Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

33歳,男性。母と母方従伯母,2人の再従姉に悪性黒色腫の家族歴がある。17歳時に腰部の黒色斑を,21歳時に左母指爪甲色素線条を切除され,それぞれ表在拡大型悪性黒色腫(SSM),末端黒子型悪性黒色腫と診断された。32歳時,背部と左下腿の黒色斑を切除され,いずれもSSM in situと診断された。これまで欧米では家族性悪性黒色腫の主要な原因遺伝子としてCDKN2A,CDK4の変異が報告されており,近年もBAP1,POT1,TERTなどの遺伝子変異が報告されている。我々が調べ得た限り本邦で過去に遺伝子解析を行った家系は2家系であるが,未だ遺伝子変異の同定はない。自験例でもwhole exome sequencingを行ったが,明らかな病的変異は認められなかった。今後さらに症例を集積し,本邦での家族性悪性黒色腫における遺伝子変異の有無や傾向を明らかにすることが望まれる。(著者抄録)

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.2340/00015555-3881

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：English  

DOI： 10.1111/1346-8138.15800

PubMed

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Wiley  

DOI： 10.1111/jdv.17020

researchmap

Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jdv.17020

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(一社)日本皮膚悪性腫瘍学会  

researchmap

Language：Japanese   Publisher：(一社)日本皮膚免疫アレルギー学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：English  

DOI： 10.1016/j.jaad.2019.12.017

PubMed

researchmap

Language：English  

DOI： 10.2340/00015555-3472

PubMed

researchmap

Language：English  

Botryomycosis is a rare chronic suppurative granulomatous infection caused by several genera of non-filamentous bacteria. The clinical and histopathological findings are similar to those of mycetoma caused by true fungi or aerobic actinomycetes. Botryomycosis is divided into cutaneous and visceral disease, with the cutaneous form being more common. Histopathology shows granules of etiologic bacteria called "sulfur granules". Botryomycosis occurs more commonly among immunocompromised patients, although some cases have also been reported in immunocompetent patients. We report the case of an 8-year-old immunocompetent boy who visited our hospital with a 4-mm diameter subcutaneous tumor with mild tenderness on his right heel for several months. We surgically removed the tumor with an initial diagnosis of epidermal cyst. Histopathology showed sulfur granules surrounded by an eosinophilic matrix, indicating the Splendore-Hoeppli phenomenon. The granules consisted of Gram-positive cocci, leading to a diagnosis of botryomycosis. The patient was successfully treated by excision and oral trimethoprim/sulfamethoxazole (240 mg b.i.d.) for 2 weeks as adjuvant therapy. No recurrence was noted following treatment. The subcutaneous tumor in this case was smaller than the typical in botryomycosis infections. We reviewed the infection duration and tumor size in reported cases of botryomycosis in immunocompetent patients. Small tumor size may suggest that the case is in an early stage; therefore, it is important to remove and investigate these lesions proactively.

DOI： 10.1111/1346-8138.15308

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

DOI： 10.1016/j.jaip.2019.05.002

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma. Early-stage MF patches or plaques often resemble inflammatory skin disorders (ISDs), including psoriasis and atopic dermatitis. Cell adhesion molecule 1 gene (CADM1), which was initially identified as a tumor suppressor gene in human non-small cell lung cancer, has been reported as a diagnostic marker for adult T-cell leukemia/lymphoma. OBJECTIVE: We investigated CADM1 expression in MF neoplastic cells, especially during early stages, and evaluated its usefulness as a diagnostic marker for MF. METHODS: We conducted a retrospective study by using immunohistochemical staining and confirmed the expression of CADM1 in MF. In addition, we compared CADM1 messenger RNA expression in microdissected MF samples and ISD samples. RESULTS: In the overall study period, 55 of 58 MF samples (94.8 %) stained positive for CADM1. None of the 50 ISD samples showed positive reactivity (P < .0001). We found CADM1 messenger RNA expression in the intradermal lymphocytes of patients with MF but not in those of patients with an ISD. LIMITATIONS: We did not conduct a validation study for MF cases in other institutions. CONCLUSIONS: CADM1-positive cells can be identified in early stages with fewer infiltrating cells and may be useful as a diagnostic marker for early-stage MF.

DOI： 10.1016/j.jaad.2018.06.025

PubMed

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：LIPPINCOTT WILLIAMS & WILKINS  

Nivolumab is an antibody against programmed cell death 1 and functions as an immune checkpoint inhibitor for various malignancies, including unresectable melanomas. Nivolumab causes several immune-related adverse events, which typically include skin rash, pneumonitis, thyroid dysfunction, hepatitis, and colitis; in rare cases, anemia may be present. There are several reports of autoimmune hemolytic anemia that has developed in response to nivolumab; however, there are few reports of pure red cell aplasia (PRCA). We describe a patient who developed PRCA during nivolumab administration. A 70-year-old Japanese woman received nivolumab for cardiac metastasis from malignant melanoma from an unknown site. Twenty-one months after nivolumab administration (31 courses), treatment was discontinued because she developed severe anemia. Blood test results indicated normocytic, normochromic anemia, and reticulocytopenia, but all other components were normal. Bone marrow aspiration showed increased megakaryocytes and decreased erythroblasts; these findings were consistent with PRCA. Anemia improved without recurrence after treatment with corticosteroids and blood transfusions. The steroid dosage was reduced gradually, and to date, the patient has not experienced recurrence of anemia. The tumor decreased in size and the patient has shown a continued response to treatment with decrease in disease for 3 years. Although it is unclear how nivolumab causes PRCA, hematological toxicities have been reported in patients treated with immunotherapy drugs. PRCA might be an unrecognized immune-mediated adverse event that did not manifest during the clinical trial phase. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.

DOI： 10.1097/CMR.0000000000000392

Web of Science

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：WILEY  

Tie-over bolster dressing after skin grafting can prolong operative time, and cause hematoma and seroma formation because of uneven pressure application. To describe the possibility of discontinuing the use of tie-over dressing, we carried out a retrospective comparative study of patients who underwent skin grafting at an institution between January 2009 and December 2014. We investigated and compared the take rate, healing period, wound infection rate and hematoma formation rate for the tie-over dressing group and the non-tie-over dressing group. Among 266 patients, 148 and 118 patients were included in the tie-over dressing group and non-tie-over dressing group, respectively. There were no significant differences between the take rate, healing period, wound infection rate and hematoma formation rate for the two groups. Multivariate analysis showed that the complete graft take rate was not significantly influenced by tie-over dressing, age, sex, graft site, graft procedure and skin graft diameter. Although the use of tie-over dressing might remain necessary on sites with a free margin, including the eyelids, lips or nostrils, because of the difficulty in using tape fixation, the present study showed that alternative dressing with polyurethane foam is also useful in most cases of skin grafting.

DOI： 10.1111/1346-8138.13916

Web of Science

PubMed

researchmap

Language：Japanese   Publisher：新潟県立がんセンター新潟病院  

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

researchmap

Language：Japanese   Publisher：金原出版  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：Japanese Dermatological Association  

&lt;p&gt;In patients who have histories of extravasation with anticancer agents, recurrent inflammation at the site of extravasation sometimes occurs when the same drug is readministered at a different site. This reaction is referred to as &quot;recall&quot;. We treated 6 patients who developed recall reactions despite having no obvious history of extravasation. One of these patients had a skin ulcer and required long-term treatment until it healed. Although the exact mechanism underlying the onset of the recall reaction is unclear, it may involve latent tissue damage caused by microleakage of pharmaceuticals.&lt;/p&gt;

DOI： 10.14924/dermatol.126.1453

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：医学書院  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：医学書院  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：医学書院  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：(公社)日本皮膚科学会  

J-GLOBAL

researchmap